BML, Inc. (MUN:BMZ)

Market Cap	730.51M +2.4%
Revenue (ttm)	819.61M +4.9%
Net Income	42.26M +23.7%
EPS	1.11 +26.7%
Shares Out	n/a
PE Ratio	17.29
Forward PE	n/a
Dividend	0.70 (3.62%)
Ex-Dividend Date	Mar 30, 2026

Volume	n/a
Open	19.60
Previous Close	19.40
Day's Range	19.50 - 19.60
52-Week Range	18.40 - 23.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About BML, Inc.

BML, Inc. provides contract clinical testing and related services in Japan. The company offers a range of laboratory testing, such as biochemical and hematologic examination; laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, allergies, genetics, and more areas, as well as develops Frontier and Symphony automation systems, which automate pre-testing from specimen sorting to dispe...

• Industry: Commercial Physical and Biological Research
• Founded: 1955
• Employees: 4,558
• Stock Exchange: Munich Stock Exchange
• Ticker Symbol: BMZ

Financial Performance

In fiscal year 2026, BML, Inc.'s revenue was 150.26 billion, an increase of 4.94% compared to the previous year's 143.19 billion. Earnings were 7.75 billion, an increase of 23.71%.

Financial numbers in JPY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 23, 2026

Data Sources Report a data error